EPIRUS Biopharmaceuticals And Ranbaxy Laboratories Announce Signing Of BOW015 Licensing Partnership For Broad Range Of Territories
Published: Jan 08, 2014
ZUG, Switzerland & NEW DELHI, India--(BUSINESS WIRE)--EPIRUS Switzerland GmbH, a wholly-owned subsidiary of Boston-based EPIRUS Biopharmaceuticals, Inc. (“EPIRUS”), and Ranbaxy Laboratories Limited (“RANBAXY”) a division of Daiichi Sankyo Company, Tokyo, today announced the signing of a licensing agreement for BOW015, a biosimilar infliximab, for the broad range of territories including India, selected South East Asian markets, North Africa and several other markets.
Help employers find you! Check out all the jobs and post your resume.